I-Mab Reveals Promising Results in Phase 1b/2 Study for Advanced Non-Small Cell Lung Cancer Treatment

I-Mab IMAB announced results from the Phase 1b/2 study of uliledlimab in combination with toripalimab (Tuoyi) in patients with treatment-naïve advanced non-small cell lung cancer.
As of April 14, 2023, 70 patients were enrolled.
Uliledlimab demonstrated a favorable safety profile up to 30mg/kg Q3W in combination with toripalimab, with most treatment-related adverse events (TRAEs) being Grade 1 or Grade 2 in severity.
In the efficacy evaluable population (n=67), the objective response rate (ORR) was 31.3% regardless of PD-L1 and CD73 expression.
Notably, patients with CD73High exhibited a higher ORR than those with CD73Low (53% vs. 18%).
The ORR increased to 63% in patients with CD73High and PD-L1 tumor proportion score (TPS)≥1%, whereas patients with CD73Low had an ORR of 20%.
At the time of data cutoff, with a median follow-up of 10.4 months, 18 out of 21 responders remained on treatment, and the median duration of response (DOR) was not reached.
Progression-free survival (PFS) and overall survival (OS) data will be analyzed when the data are fully mature.
Price action: IMAB shares closed at $2.99 on Thursday.